Neoantigen Targeted Therapies Market Estimated to Experience a Hike in Growth by 2035
Cancer immunotherapy is increasingly moving toward treatments tailored to the molecular characteristics of individual tumors. Neoantigens, which arise from tumor-specific mutations, provide potential targets that can distinguish cancer cells from healthy tissue.
The neoantigen-targeted therapies market was valued at approximately USD 661 million in 2025 and is projected to reach USD 807 million in 2026, with strong growth expected through 2030.
Advances in genomic sequencing and bioinformatics have made it increasingly feasible to identify tumor-specific mutations and select potential neoantigens. Developers can then design personalized vaccines or cellular therapies aimed at generating an immune response against those targets.
mRNA-based approaches have attracted significant attention because they can potentially encode multiple selected neoantigens in a single therapeutic construct. Other strategies include dendritic cell vaccines, DNA or RNA-based vaccines, protein and peptide approaches, and tumor-infiltrating lymphocyte therapies.
Combination treatment is another important area. Neoantigen therapies are being evaluated alongside immune checkpoint inhibitors such as pembrolizumab, nivolumab and other established immunotherapies.
Recent clinical developments continue to support the field. Moderna and Merck reported five-year follow-up data from a Phase II trial involving an individualized neoantigen mRNA vaccine combined with Keytruda in melanoma patients in May 2026.
The major challenges include the time and cost required for individualized manufacturing, reliable neoantigen prediction and ensuring that selected targets generate meaningful immune responses.
As sequencing and computational prediction improve, these challenges could gradually become more manageable. The long-term opportunity lies in integrating genomic information with scalable manufacturing and personalized treatment workflows.
For more information on the Neoantigen Targeted Therapies Market, visit:
https://www.rootsanalysis.com/....reports/neoantigen-t